First systematic review of ADR related to asthma drugs

Asthma is a disease that affects 230 million people around the world The treatment of asthma follows the national and international evidence-based guidelines, but there are differences in treatment response among individuals, which are related to a variety of factors (disease subtype and severity, as well as environmental factors) The patient's genotype also affects the outcome of asthma treatment Recently, Charlotte king and other researchers from the University of Liverpool reviewed the adverse drug reactions (ADRs) related to asthma drugs in pharmacogenomics research, and conducted a pharmacogenomics survey on the members of children's asthma Federation The aim of this study is to determine the current priority of ADR in asthma drug genomic research and the future research priority The findings are published in the journal the pharmacology journal There are few pharmacogenomic studies on adverse reactions of asthma drugs This is the first systematic review Considering the harm of antiasthmatic drugs and their relationship with individual genetic variability, researchers selected five research results as a systematic review These five studies are respectively a study to detect adverse reactions of inhaled short acting β 2-receptor agonist (Saba); an analysis The study of long-acting β 2-receptor agonist (Laba); three studies on the use of corticosteroids Candidate gene methods were used in Saba and Laba studies, while genome-wide association analysis (GWAS) was used in three corticosteroid studies In the end, the researchers identified six different adverse drug reactions related to pharmacogenomics, but these are only a small part of the pharmacogenomics of asthma The researchers say the study has limitations because the quality of the data produced depends on the quality of the publications and there is a lack of qualified articles covering a range of drugs and ADRs, which have a relatively small sample size, and the diversity of ADRs precludes meta-analysis However, the recognition and prioritization of ADR by members of the children's asthma Federation is a positive signal, indicating that future pharmacogenomics research may include more ADR and efficacy research Reference source: doi.org/10.1038/s41397-019-0140-y denigui statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.